Loading...
Loading...
Browse all stories on DeepNewz
VisitHow many H5N1 vaccine doses will be administered in the UK by the end of 2025?
Less than 1 million • 25%
1-5 million • 25%
5-10 million • 25%
More than 10 million • 25%
UK Health Security Agency reports
UK Orders Five Million Bird Flu Vaccines Amid H5N1 Mutation Risk
Dec 31, 2024, 02:07 PM
The UK government has ordered five million doses of avian influenza (H5N1) vaccines to prepare for the potential spread of the virus among humans. This move comes amid growing concerns that the virus, which has already shown mutations in recent cases, could evolve to become transmissible between humans. A recent study highlighted that the virus is one mutation away from being able to attach to human cell receptors, although additional changes would be required for sustained human-to-human transmission. In the United States, outbreaks in dairy cattle and poultry have led to sporadic human infections, with most cases being mild. However, severe cases, such as a 13-year-old Canadian girl infected with the D1.1 genotype and a Louisiana patient with H5N1 Clade B.2.3.4.4B, have raised alarms due to genetic mutations observed in the virus during these infections. California has declared an emergency over infected cattle herds. Experts emphasize the need for vigilant surveillance, enhanced biosecurity measures, and pandemic preparedness to mitigate risks. The UK Health Security Agency has partnered with vaccine manufacturer CSL Seqirus, which is also prepared to produce over 100 million doses if necessary.
View original story
3 to 5 million • 25%
Less than 1 million • 25%
1 to 3 million • 25%
More than 5 million • 25%
1-3 million doses distributed • 25%
Over 5 million doses distributed • 25%
0-1 million doses distributed • 25%
3-5 million doses distributed • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Other • 25%
Elderly population • 25%
Healthcare workers • 25%
Children • 25%
Community centers • 25%
Government clinics • 25%
Private hospitals • 25%
Pharmacies • 25%
1 to 5 million • 25%
Less than 1 million • 25%
5 to 10 million • 25%
More than 10 million • 25%
Widely available vaccine • 25%
Other interventions prioritized • 25%
Limited availability vaccine • 25%
No vaccine developed • 25%
Less than 100 • 25%
100 to 500 • 25%
More than 1000 • 25%
501 to 1000 • 25%
Yes • 50%
No • 50%
0-10 • 25%
More than 100 • 25%
51-100 • 25%
11-50 • 25%